Bausch + Lomb trumps failed Valeant bid for ISTA with $500m deal
This article was originally published in Scrip
Eye care firm Bausch + Lomb has agreed to acquire ISTA Pharmaceuticals for $9.10 per share, or around $500 million in total, in cash. The deal represents a premium of 10% to ISTA's share price on 23 March, the last trading day before the transaction went public yesterday, and trumps the salvo of hostile offers from Valeant Pharmaceuticals, which rapidly escalated its bid from $6.50 per share last December through $7.50 to $8.50, but then withdrew from the running as its debt was downgraded by Moody's (scripintelligence.com, 31 January 2012).
You may also be interested in...
A strong year is predicted for biopharma business with investment and deal making set to continue apace. Executives across industry share their forecasts for the year ahead.
Around 100 executives highlight the hot areas to watch on the R&D front in 2021. From cancer to CNS and from regenerative medicine to real world data, expectations are high on many fronts.
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.